In an­oth­er win for mR­NA, Cure­Vac ex­ecs de­tail the new PhI read­out of their vac­cine da­ta and why they’re so pumped about it

Pfiz­er may be out front in the race to de­vel­op the first new mR­NA vac­cine for Covid-19. But the clin­i­cal ri­vals to the phar­ma gi­ant and BioN­Tech, which de­vel­oped the vac­cine, are still hell bent on jump­ing in fast enough to play a big role in de­feat­ing the cur­rent pan­dem­ic — and get­ting set up for what­ev­er fu­ture out­breaks may bring us.

To that end, the Cure­Vac team $CVAC is post­ing their Phase I da­ta to­day — spelling out what re­searchers were able to de­ter­mine among 251 pa­tients af­ter of­fer­ing up the gen­er­al top-line re­sults a few days ago.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.